Comprehensive viral vector analytics for cell and gene therapy

OXB supports programs across the EU, US, and worldwide, offering a global footprint for viral vector programs supporting both cell and gene therapies.

Yes. We provide remote analytics strategy support, CMC documentation, and regulatory guidance to clients worldwide.

Absolutely. Our labs are CGMP-compliant, FDA-registered, and equipped with BSL-3 RCL testing capabilities, ensuring regulatory-ready analytics for clinical and commercial programs.

Yes. Our global presence and standardized protocols enable us to deliver analytics and quality control support for both clinical trials and commercial supply across multiple regions.

OXB provides a broad suite of potency assays, including transduction efficiency, p24, enzymatic activity, and functional readouts, that demonstrate product quality, consistency, and mechanism of action. These assays are validated and have been accepted by global health authorities, supporting both clinical and commercial submissions.

Yes. We design and validate bespoke assays tailored to unique viral vector products, including in-house CGMP RCL testing from BSL-3 facilities and product-specific potency assays.

Turnaround times vary depending on the assay and program, but our high-throughput automation and validated in-house methods enable faster GMP batch release and regulatory submissions.

OXB’s QC scientists and analysts are highly trained in advanced assay development, validation, and lifecycle management. Their expertise ensures robust analytical packages that meet global standards, with a strong focus on method robustness, accuracy, and compliance.